MRI contrast developer Epix Pharmaceuticals reported revenue of $1.4 million in the second quarter, compared with $1.1 million in the second quarter of 2005.
The Cambridge, MA, company also cut its net loss, posting a net loss of $3.2 million, compared with a net loss of $7.1 million in the same quarter a year ago.
For the first six months of 2006, revenues remained stable at $3.1 million, the same as the 2005 period. The firm's net loss was $7.7 million, compared with a net loss of $13.4 million in the same six-month period of 2005.
Epix shareholders are scheduled to vote on August 15 on the company's proposed merger with Predix, a privately held pharmaceuticals company based in Lexington, MA.
By AuntMinnie.com staff writers
August 7, 2006
Related Reading
FDA extends Epix's Vasovist appeal, July 31, 2006
Epix retains rights to EP-2104R, July 13, 2006
Epix files Vasovist appeal with FDA, July 4, 2006
Astrue resigns from Epix, May 8, 2006
Epix to buy Predix Pharmaceuticals, April 3, 2006
Copyright © 2006 AuntMinnie.com
